We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Ionis Pharmaceuticals Earns $5 Million Milestone Payment
News

Ionis Pharmaceuticals Earns $5 Million Milestone Payment

Ionis Pharmaceuticals Earns $5 Million Milestone Payment
News

Ionis Pharmaceuticals Earns $5 Million Milestone Payment

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Ionis Pharmaceuticals Earns $5 Million Milestone Payment"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Ionis Pharmaceuticals, Inc. has announced that it has earned a $5 million milestone payment from Biogen associated with the validation of an undisclosed target to treat patients with an undisclosed neurological disorder.

Ionis and Biogen have a broad strategic collaboration to develop drugs to treat patients with neurological disorders. For this newest target, Ionis will continue to evaluate the target with the goal of advancing this program into development.

"Our strategic collaboration with Biogen is very successful. Our most advanced program, nusinersen, is currently in Phase 3 clinical studies, and we have a number of other drugs in development. We benefit tremendously from the expertise Biogen brings to our partnered programs. We also benefit financially as these programs advance. Across our four collaborations, we have generated more than $350 million from Biogen as our programs have advanced," said B. Lynne Parshall, chief operating officer at Ionis. "As we enter 2016, we expect to continue to expand our collaboration with Biogen as we identify new targets and move new antisense drugs into development."

Advertisement